Category: pyrimidines

Bae, Seyeon team published research on Cell Reports in 2021 | 65-86-1

Reference of 65-86-1, Orotic acid anhydrous is a hydrogen bonding interaction that can be found in biological systems. It plays a role in the physiological effects of orotic acid, which is a metabolite of uridine and an intermediate in the synthesis of pyrimidine nucleotides. Orotic acid has antimicrobial properties and has been shown to inhibit enzyme activities involved in energy metabolism, such as polymerase chain reaction (PCR) and adenosine triphosphate (ATP) synthase. Orotic acid also inhibits the growth of bacteria, fungi, and parasites. Orotic acid anhydrous is used for treating myocardial infarcts or brain functions. The untreated group was given no treatment at all.
Orotic acid, also known as orotate or orotsaeure, belongs to the class of organic compounds known as pyrimidinecarboxylic acids. These are pyrimidines with a structure containing a carboxyl group attached to the pyrimidine ring. Orotic acid exists as a solid, slightly soluble (in water), and a moderately acidic compound (based on its pKa). Orotic acid has been found in human liver and pancreas tissues, and has also been primarily detected in saliva, feces, urine, and blood. Within the cell, orotic acid is primarily located in the cytoplasm and mitochondria. Orotic acid exists in all eukaryotes, ranging from yeast to humans. Orotic acid participates in a number of enzymatic reactions. In particular, Orotic acid can be biosynthesized from L-dihydroorotic acid and quinone; which is mediated by the enzyme dihydroorotate dehydrogenase (quinone), mitochondrial. In addition, Orotic acid and phosphoribosyl pyrophosphate can be converted into orotidylic acid through its interaction with the enzyme uridine monophosphate synthetase isoform a. In humans, orotic acid is involved in the pyrimidine metabolism pathway. Orotic acid is also involved in several metabolic disorders, some of which include the mngie (mitochondrial neurogastrointestinal encephalopathy) pathway, dihydropyrimidinase deficiency, UMP synthase deficiency (orotic aciduria), and Beta ureidopropionase deficiency. Outside of the human body, orotic acid can be found in a number of food items such as green vegetables, alaska blueberry, chickpea, and colorado pinyon. This makes orotic acid a potential biomarker for the consumption of these food products. Orotic acid is a potentially toxic compound. Orotic acid has been found to be associated with several diseases known as phosphoenolpyruvate carboxykinase deficiency 1, cytosolic and hyperornithinemia-hyperammonemia-homocitrullinuria; orotic acid has also been linked to several inborn metabolic disorders including n-acetylglutamate synthetase deficiency, lysinuric protein intolerance, and ornithine transcarbamylase deficiency.
Orotic acid appears as white crystals or crystalline powder.
Orotic acid is a pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6. It has a role as a metabolite, an Escherichia coli metabolite and a mouse metabolite. It derives from a uracil. It is a conjugate acid of an orotate., 65-86-1.

The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives, 65-86-1, formula is C5H4N2O4, Name is 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid. including the nucleotides cytosine, thymine and uracil, thiamine (vitamin B1) and alloxan. Reference of 65-86-1.

Bae, Seyeon;Park, Peter Sang Uk;Lee, Yeji;Mun, Se Hwan;Giannopoulou, Eugenia;Fujii, Takayuki;Lee, Kelvin P.;Violante, Sara Nunes;Cross, Justin R.;Park-Min, Kyung-Hyun research published 《 MYC-mediated early glycolysis negatively regulates proinflammatory responses by controlling IRF4 in inflammatory macrophages》, the research content is summarized as follows. MYC activates different metabolic programs in a cell-type- and cell-status-dependent manner. However, the role of MYC in inflammatory macrophages has not yet been determined Metabolic and mol. analyses reveal that MYC, but not hypoxia inducible factor 1 (HIF1), is involved in enhancing early glycolytic flux during inflammatory macrophage polarization. Ablation of MYC decreases lactate production by regulating lactate dehydrogenase (LDH) activity and causes increased inflammatory cytokines by regulating interferon regulatory factor 4 (IRF4) in response to lipopolysaccharide. Moreover, myeloid-specific deletion of MYC and pharmacol. inhibition of the MYC/LDH axis enhance inflammation and the bacterial clearance in vivo. These results elucidate the potential role of the MYC/LDH/IRF4 axis in inflammatory macrophages by connecting early glycolysis with inflammatory responses and suggest that modulating early glycolytic flux mediated by the MYC/LDH axis can be used to open avenues for the therapeutic modulation of macrophage polarization to fight against bacterial infection.

Reference of 65-86-1, Orotic acid anhydrous is a hydrogen bonding interaction that can be found in biological systems. It plays a role in the physiological effects of orotic acid, which is a metabolite of uridine and an intermediate in the synthesis of pyrimidine nucleotides. Orotic acid has antimicrobial properties and has been shown to inhibit enzyme activities involved in energy metabolism, such as polymerase chain reaction (PCR) and adenosine triphosphate (ATP) synthase. Orotic acid also inhibits the growth of bacteria, fungi, and parasites. Orotic acid anhydrous is used for treating myocardial infarcts or brain functions. The untreated group was given no treatment at all.
Orotic acid, also known as orotate or orotsaeure, belongs to the class of organic compounds known as pyrimidinecarboxylic acids. These are pyrimidines with a structure containing a carboxyl group attached to the pyrimidine ring. Orotic acid exists as a solid, slightly soluble (in water), and a moderately acidic compound (based on its pKa). Orotic acid has been found in human liver and pancreas tissues, and has also been primarily detected in saliva, feces, urine, and blood. Within the cell, orotic acid is primarily located in the cytoplasm and mitochondria. Orotic acid exists in all eukaryotes, ranging from yeast to humans. Orotic acid participates in a number of enzymatic reactions. In particular, Orotic acid can be biosynthesized from L-dihydroorotic acid and quinone; which is mediated by the enzyme dihydroorotate dehydrogenase (quinone), mitochondrial. In addition, Orotic acid and phosphoribosyl pyrophosphate can be converted into orotidylic acid through its interaction with the enzyme uridine monophosphate synthetase isoform a. In humans, orotic acid is involved in the pyrimidine metabolism pathway. Orotic acid is also involved in several metabolic disorders, some of which include the mngie (mitochondrial neurogastrointestinal encephalopathy) pathway, dihydropyrimidinase deficiency, UMP synthase deficiency (orotic aciduria), and Beta ureidopropionase deficiency. Outside of the human body, orotic acid can be found in a number of food items such as green vegetables, alaska blueberry, chickpea, and colorado pinyon. This makes orotic acid a potential biomarker for the consumption of these food products. Orotic acid is a potentially toxic compound. Orotic acid has been found to be associated with several diseases known as phosphoenolpyruvate carboxykinase deficiency 1, cytosolic and hyperornithinemia-hyperammonemia-homocitrullinuria; orotic acid has also been linked to several inborn metabolic disorders including n-acetylglutamate synthetase deficiency, lysinuric protein intolerance, and ornithine transcarbamylase deficiency.
Orotic acid appears as white crystals or crystalline powder.
Orotic acid is a pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6. It has a role as a metabolite, an Escherichia coli metabolite and a mouse metabolite. It derives from a uracil. It is a conjugate acid of an orotate., 65-86-1.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Application of cas: 18592-13-7 | Sugiyama, N. et al. published an article in 2008

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Recommanded Product: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Recommanded Product: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione《Molecular recognition of Langmuir-Blodgett polymer films containing uracil groups》 was published in 2008. The authors were Sugiyama, N.;Hirakawa, M.;Zhu, H.;Takeoka, Y.;Rikukawa, M., and the article was included in《Colloids and Surfaces, A: Physicochemical and Engineering Aspects》. The author mentioned the following in the article:

Novel copolymers, poly(acryroyloxymethyluracil-co-hexylacrylamide)s (poly(AU-co-HAAm)s), were synthesized by radical copolymerization with different monomer ratios. The poly(AU-co-HAAm)s formed stable monolayers at the air-water interface and could be deposited on solid substrates as Y-type films by the vertical dipping method. The mol. structure of poly(AU-co-HAAm) LB films was determined by reflection absorption and transmission FTIR, and x-ray diffraction measurements. Evidence for preferential orientation of both the AU and HAAm units was found. The LB films deposited on quartz crystal microbalance substrates adsorbed adenosine mols., and the adsorbed amounts increased with higher contents of uracil groups in poly(AU-co-HAAm)s. Some morphol. changes of LB films were also observed by at. force microscopy (AFM) after the mol. recognition.6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) were involved in the experimental procedure.

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Recommanded Product: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

New progress of cas: 18592-13-7 | Biochemical Pharmacology 1984

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Name: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Niedzwicki, John G.;Iltzsch, Max H.;El Kouni, Mahmoud H.;Cha, Sungman published 《Structure-activity relationship of pyrimidine base analogs as ligands of orotate phosphoribosyltransferase》 in 1984. The article was appeared in 《Biochemical Pharmacology》. They have made some progress in their research.Name: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione The article mentions the following:

Eighty pyrimidine base analogs were evaluated as inhibitors of mouse liver orotate phosphoribosyltransferase (I) (EC 2.4.2.10). Based on these findings and an extensive literature review, a structure-activity relation was formulated for the binding of pyrimidine base analogs to I. A basis for the rational design of new inhibitors of I is provided, and several such compounds are proposed. Addnl., 4,6-dihydroxypyrimidine was found to be a potent I inhibitor. Eleven I inhibitors were also evaluated as inhibitors of orotidine 5′-monophosphate decarboxylase (II) (EC 4.1.2.23). 5-Azauracil, 5-azaorotate, and barbituric acid inhibited II significantly after preincubation with PRPP and MgCl2 in the presence of cytosol.6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) were involved in the experimental procedure.

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Name: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Hansen, Steen Uldall et al. published new experimental results with the assistance of cas: 18592-13-7

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Name: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Hansen, Steen Uldall;Bols, Mikael published 《1-Azaribofuranoside analogs as designed inhibitors of purine nucleoside phosphorylase. Synthesis and biological evaluation》. The research results were published in《Acta Chemica Scandinavica》 in 1998.Name: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione The article conveys some information:

Pyrrolidine analogs of 2-deoxyribofuranose, having nitrogen in place of anomeric carbon, have been synthesized as potential transition state analogs of enzymic nucleoside cleavage. Efficient synthetic methods were developed that allowed the synthesis of a wide range of 4-substituted 3-hydroxypyrrolidines starting from pyrroline and using opening of the pyrrolidine 3,4-epoxide with carbon nucleophiles. Among the compounds synthesized were the 4-cyano-, 4-hydroxymethyl and 4-carboxymethyl derivatives From the hydroxymethyl derivative, N-alkylation with chloromethyluracil gave an inosine analog. The new compounds were tested for inhibition of human erythrocyte purine nucleoside phosphorylase. Furthermore, a solid-phase synthesis of 1′-azanucleoside analogs was developed.6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) were involved in the experimental procedure.

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Name: 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Explore more uses of cas: 18592-13-7 | Tetrahedron

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Electric Literature of C5H5ClN2O2) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Crigg, Ronald;Myers, Peter;Somasunderam, Anoma;Sridharan, Visuvanathar published 《X:Y-ZH systems as potential 1,3-dipoles. Part 36. 1,5-Electrocyclization processes via oxidation of tertiary amines. Pyrrolodihydroisoquinolines and -dihydro-β-carbolines》. The research results were published in《Tetrahedron》 in 1992.Electric Literature of C5H5ClN2O2 The article conveys some information:

A range of tertiary N-allylamines, e.g. I, derived from 1,2,3,4-tetrahydroisoquinoline undergo oxidative cyclization induced by Ag2CO3 to give pyrrolodihydroisoquinolines, e.g., II, in moderate to good yield. Analogous oxidative cyclizations are reported for N-allyltetrahydro-β-carbolines and a pyrrolidine. The reactions proceed via formation of a 1,5-dipole followed by an electrocyclization and subsequent aromatization. And 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) was used in the research process.

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Electric Literature of C5H5ClN2O2) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Cas: 18592-13-7 | Liu, Houmei et al. made new progress in 2014

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 SDS of cas: 18592-13-7) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Liu, Houmei;Guo, Yong;Wang, Xusheng;Liang, Xiaojing;Liu, Xia;Jiang, Shengxiang published 《A novel fullerene oxide functionalized silica composite as stationary phase for high performance liquid chromatography》. The research results were published in《RSC Advances》 in 2014.SDS of cas: 18592-13-7 The article conveys some information:

Hydrophilic interaction liquid chromatog. has been widely used for separating hydrophilic compounds and the development of new stationary phases for HILIC is significant. In this study, fullerene oxide was successfully assembled onto silica microspheres to form a FO-modified silica stationary phase. The synthesized material was characterized by elemental anal., transmission electron microscopy, Raman spectroscopy and contact angle anal. The chromatog. properties of the stationary phase were investigated in HILIC mode for anal. of nucleosides, nucleobases, water soluble vitamins, amino acids and saccharides. Good separations of these compounds were achieved on the resulting column. Compared with the aminopropylated silica column, FO/SiO2 column exhibited better separation efficiency. This study also investigated the effect of various exptl. factors on the retention of the polar stationary phases, such as acetonitrile content and salt concentration in the mobile phase.6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) were involved in the experimental procedure.

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 SDS of cas: 18592-13-7) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

New progress of cas: 18592-13-7 | Chemistry – A European Journal 1997

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Related Products of 18592-13-7) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Cusack, Lucy;Rao, S. Nagaraja;Fitzmaurice, Donald published 《Heterosupramolecular chemistry: self-assembly of an electron donor (TiO2 nanocrystallite)-acceptor (viologen) complex》. The research results were published in《Chemistry – A European Journal》 in 1997.Related Products of 18592-13-7 The article conveys some information:

A TiO2 nanocrystallite has been modified to recognize and selectively bind, by complementary hydrogen bonding, a uracil substrate incorporating a viologen moiety. Band-gap excitation of the self-assembled donor (TiO2 nanocrystallite)-acceptor (viologen) complex results in electron transfer. Some implications of these findings for the self-assembly of functional nanostructures containing both condensed phase and mol. components are considered. To complete the study, the researchers used 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) .

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Related Products of 18592-13-7) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Learn more about cas: 18592-13-7 | Journal of Heterocyclic Chemistry 1986

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Computed Properties of C5H5ClN2O2) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Wade, James J. published 《Synthesis of imidazo[1,5-c]pyrimidine derivatives》. The research results were published in《Journal of Heterocyclic Chemistry》 in 1986.Computed Properties of C5H5ClN2O2 The article conveys some information:

Two complementary procedures, each starting from 6-(aminomethyl)uracil (I), were used to prepare imidazopyrimidines II (R = H, Me, Pr, CHMe2, CMe3, Ph; R1 = morpholino, OMe, SPr, Me). I was prepared by ammoxidation of 6-(chloromethyl)uracil. In the first procedure, I was acylated and then cyclodehydrated by reaction with POCl3 to give a separable mixture of II and III (R1 = Cl). The relative product distribution is subject to some control by the choice of the acyl substituent on the starting uracil. II (R1 = Cl) were derivatized by reaction at the 5-position with various nucleophiles, although the 7-chloro substituent is unreactive. An alternative synthetic method proceeds from I in six steps, i.e. protection as the phthalimide, chlorination, nucleophilic substitution, deprotection, acylation, and cyclodehydration, to give II (R1 = SMe). These compounds were also derivatized by nucleophilic substitution at the 5-position.6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) were involved in the experimental procedure.

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Computed Properties of C5H5ClN2O2) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

New progress of cas: 18592-13-7 | Pakistan Journal of Pharmaceutical Sciences 2018

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Application In Synthesis of 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Application In Synthesis of 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione《Some novel piperidine analogues having strong alpha glucosidase inhibition》 was published in 2018. The authors were Rafiq, Kiran;Saify, Zafar Saied;Nesar, Shagufta;Faiyaz, Ambreen;Muhammad, Iyad Naeem, and the article was included in《Pakistan Journal of Pharmaceutical Sciences》. The author mentioned the following in the article:

In the present work some hydroxy piperidine analogs have been synthesized and analyzed for their hypoglycemic effect through glucosidase inhibition owing to the structural resemblance with nojirimycin. The activity was done by spectral absorbance anal. using acarbose as standard Two analogs 1-(1”-phenoxypropyl)-4-phenyl-4-hydroxy piperidinium hydrobromide and 1-(1”-adamantan acyl)-4-(4′-bromophenyl)-4-hydroxy piperidinium hydrobromide were found to pose excellent activity having 87.4 and 54.7% inhibition resp., hence strengthening the idea of studying piperidine analogs as glucosidase inhibitors due to structural similarity with nojirimycin. The experimental procedure involved many compounds, such as 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) .

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Application In Synthesis of 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Cas: 18592-13-7 | Singh, Chatar et al. made new progress in 1999

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Reference of 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference of 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dioneIn 1999, Singh, Chatar;Singh, S.;Pandey, Seema;Tripathi, P. K. published 《Vibrational spectra of 6-chloromethyluracil》. 《Asian Chemistry Letters》published the findings. The article contains the following contents:

Laser Raman and IR spectra of 6-(chloromethyl)uracil (I) were recorded and analyzed on the basis of Cs point-group symmetry. The absence of any O-H stretching vibration and the appearance of C=O stretching modes as strong bends in the spectra of I suggest that no tautomerism occurs, and the compound exists in the ketone form. The experimental procedure involved many compounds, such as 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7) .

6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione (cas: 18592-13-7 Reference of 6-(Chloromethyl)pyrimidine-2,4(1H,3H)-dione) was used in the synthesis of: 5-bromo-6-(chloromethyl)uracil, pteridine compounds, potential anticancer agents, substituted uracil pyridinium compounds, potential inhibitors of thymidine phosphorylase.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia